Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the ongoing coronavirus disease 2019 (COVID-19) global pandemic. Since its discovery, millions of cases have been recorded worldwide, with hundreds of thousands of deaths. The pathophysiology of SARs-CoV-2 in the lungs involves viral interaction with cells expressing angiotensin-converting enzyme 2 (ACE2) in the lung. This interaction is thought to involve ACE2-mediated cellular viral entry, tissue damage and systemic release of cytokines. This ACE2 receptor is also expressed throughout the airway tract, including the small airways. Available clinical data have highlighted that COVID-19 is associated with a long-term risk of persistent small airway disease as a result of small airway trapping, manifesting as mosaic hypoattenuation on computed tomography (CT) images, especially in patients with severe disease. This small airway disease could result from direct infection of the small airways by SARS-CoV-2. Being small in diameter, these small airways are susceptible to occlusion by inhaled toxins or pathogens, or by inflammatory damage. Small airway disease has also been known to be associated with a complication with the previous Middle East respiratory syndrome (MERS) and SARS respiratory infections.

Available clinical data have also highlighted that COVID-19 is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. The evidence to date is in keeping with the theory that the thrombotic manifestations of COVID-19 are due to the ability of SARS-CoV-2 to invade pulmonary capillary endothelial cells via ACE2 expressed on the endothelial cell surface. This prothrombotic state is said to be a risk factor for perfusion abnormalities at the pulmonary level. Pulmonary microvascular thrombosis was reported as a complication of acute respiratory distress syndrome (ARDS) during previous coronavirus outbreaks. However, this feature appears to be more pronounced in severe SARS-CoV-2 infection.

At our nuclear medicine department, we have performed lung ventilation and perfusion imaging in a number of non-hospitalised patients diagnosed with COVID-19, for the diagnosis of pulmonary embolism (PE) with a ventilation perfusion (VQ) single-photon emission computed tomography/computed tomography (SPECT/CT) scan. These patients presented with persistent or new-onset cardiopulmonary symptoms and raised D-dimer levels after worsening or new onset of cardiopulmonary symptoms after the diagnosis of COVID-19.
de-isolation. Published data from our facility showed that lung perfusion abnormalities were not uncommon in these patients during the first wave of the pandemic.\textsuperscript{[17,18]} These perfusion abnormalities could be associated with PE, mosaic perfusion, perfusion shunting and pulmonary infiltrates.\textsuperscript{[17]} However, we observed that a subset of these patients had lung perfusion abnormalities that persisted, despite the fact that they had been on long-term antiocoagulation therapy. This subset of patients also had their perfusion defects matched with a ventilation defect and mosaic hypoattenuation on CT. It has been observed in the literature that there are some post-COVID-19 patients with persistent respiratory symptoms who present with hypoattenuated areas in their lungs on CT.\textsuperscript{[6,7]} These findings, based on their CT characteristics, have been suggested to be in keeping with air trapping from small airway disease and a secondary reflex vasoconstriction of the pulmonary capillaries.\textsuperscript{[6,7]} We suspect that this is part of the process we are seeing on functional imaging, presenting as persistently matched ventilation and perfusion defects. We are also not sure if it is solely due to small airway trapping, pulmonary microthrombosis or a combination of both.

Our aim in the present study is to demonstrate with VQ scans that especially during the earlier phase of the pandemic, this process also occurred in non-hospitalised patients with a milder form of COVID-19, and is persistent over a long period of time. We are worried that the persistence of these perfusion defects might lead to more severe complications later on in life.

**Methods**

**Study design and location**

The study was a retrospective cohort study conducted in a tertiary institution.

**Study population**

We reviewed all the perfusion-only SPECT/CT and VQ SPECT/CT studies of 412 patients who were investigated for PE between July 2020 and June 2021. Seventy-eight of these patients who were being investigated for PE as a complication of COVID-19 were included in the study and had their VQ scans evaluated. All baseline scans were performed within 30 days of the diagnosis of COVID-19. Nine patients who had at least one follow-up scan also had those scans reviewed in this study.

**Inclusion criteria**

- de-isolated non-hospitalised patients diagnosed with COVID-19 being investigated for PE
- age $\geq$18 years
- raised D-dimer levels
- had a VQ SPECT/CT study.

**Exclusion criteria**

- all patients without a diagnosis of COVID-19
- patients who had a VQ SPECT study only, without a CT component
- hospitalised patients or patients with severe disease.

**Equipment**

Ventilation studies were performed with 20 - 25 mCi of technetium-99m metastable diethylenetriamine pentaacetate ($^{99m}$Tc DTPA), using the SmartVent radioaerosol delivery system (Diagnostic Imaging Ltd, UK). Appropriate precautions were taken by the radiographers during ventilation of these patients and none of the staff members or patients, to the best of our knowledge, contracted COVID-19 from this ventilation procedure. Perfusion studies were performed with 3 - 5 mCi of $^{99m}$Tc macro-aggregated albumin (MAA). Images were acquired with either a 16-slice SPECT/CT camera (Siemens Symbia T16 TruePoint; Siemens Medical Solutions, USA) or a 2-slice SPECT/CT camera (Siemens Symbia T2 TruePoint; Siemens Medical Solutions, USA). Both cameras are dual-headed gamma cameras, with similar workstations and processing units.

**Acquisition protocol**

Both gamma cameras were equipped with a low-energy high-resolution collimator. SPECT CT/CT imaging was acquired immediately after ventilation of the radioaerosol at 15 s/stop, with 3° steps, in a 128 × 128 matrix. Then perfusion SPECT imaging was acquired after injection of the perfusion tracer at 12 s/stop, with 3° steps, in a 128 × 128 matrix. This was followed by a low-dose non-contrast chest CT scan, with the patient remaining in the same position.

**Image processing**

Images were processed using the Syngo (Siemens, USA) workstations for both gamma cameras. SPECT/CT images were reconstructed using an iterative algorithm, and SPECT/CT fusion images were obtained using the multimodality Syngo imaging software on the workstation.

**Data analysis**

Data from each patient were collected using Excel 2019 (Microsoft Corp., USA) and analysed using the statistical package Stata version 16 (StataCorp, USA).

**Ethical approval**

Ethics approval was obtained from the Health Sciences Research Ethics Committee at the University of the Free State (ref. no. UFS-HSD2021/1575).

**Results**

Seventy-eight patients were enrolled during the study period. The median (interquartile range) age was 45 (41 - 58) years, and the majority (88.5%) were females. Twenty-two (28.2%) of these patients had matching segmental VQ defects with mosaic attenuation on CT. All 22 patients had a baseline VQ SPECT/CT study performed within 1 month of the diagnosis of COVID-19. Nine of the 22 patients (41%) had at least one follow-up VQ SPECT/CT performed after the baseline. These 9 patients initially had a non-diagnostic study for PE and were referred for follow-up studies by the referring doctor. Of the 9 patients who had at least one follow-up study, 100% had persistent matching perfusion defects on their follow-up studies. Six of these patients (54.5%) were on long-term therapeutic antiocoagulation as they were also diagnosed with PE during the same period of the study. Ten (45.5%) of the patients had a single matched perfusion defect, 9 (40.9%) had 2 matched perfusion defects, 2 (9.1%) had 4 matched perfusion defects, while only 1 (4.5%) had 3 matched perfusion defects.

**Discussion**

Our data suggest that during the early phase of the pandemic, and with a very high index of suspicion based on our scan findings, either pulmonary microthrombosis, air trapping from alveolar damage or both could occur in non-hospitalised patients with a milder form of COVID-19. In our study, 28.2% of non-hospitalised de-isolated COVID-19 patients who presented for a VQ scan in our facility to rule out PE presented with scan findings associated with matching ventilation and perfusion abnormalities, with mosaic...
hypooptenuation on CT. This is a finding we would like to refer to as COVID-19 mosaic hypoperfusion (Figs 1 and 2). To our knowledge, this is the first African study reporting on ventilation and perfusion follow-up outcomes after SARS-CoV-2 infection, up to a year after initial presentation. Just as in our patient population, it is well known that some patients who have recovered from COVID-19 infection later present with sequelae. It has been reported that >80% of patients report the persistence of at least one symptom after recovery from COVID-19, with dyspnoea being the most commonly reported symptom. In our study population, 83% of the patients presented with persistent shortness of breath after de-isolation (Fig. 3).

We had an average follow-up period of 9 months. All the follow-up patients, including all 6 patients followed up after 1 year, had persistent matching VQ defects, with mosaic hypooptenuation on their follow-up studies (Figs 4 and 5). A Swiss COVID-19 multicentre prospective study published in 2021 reported mosaic hypooptenuation in known COVID-19 patients 4 months after recovery. In their study, these findings, which were likely due to small airway disease, were more common in those patients who presented with severe disease. Our study has shown that these findings remain persistent even after 1 year, and that they can also occur in patients diagnosed with a milder form of the disease. Ebner et al., in a letter to the editor, confirmed the presence of areas of mosaic hypooptenuation in the lungs of patients who had recovered from COVID-19, 3 months later. They also concluded that these CT findings are likely due to small airway disease. Due to the limitation of a CT-only scan, these studies do not have adequate and clear information on the state of lung perfusion in these patients. In our study, the VQ scan was able to demonstrate that these patients also have matching perfusion abnormalities. This leads us to believe that pulmonary microthrombosis, due to the ability of SARS-CoV-2 to invade pulmonary capillary endothelial cells, could also be an added pathological finding in these patients.

Autopsy findings have shown that, in addition to the features of diffuse alveolar damage found in severe COVID-19 patients, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in up to 80% of lungs examined at autopsy. Most of the imaging diagnosis of pulmonary microthrombosis has been done on dual-energy CT, where the presence of lung parenchymal hypooptenuation in the absence of PE is strongly indicative of pulmonary microthrombosis. However, this modality does not give sufficient information on lung ventilation, and is not usually used for follow-up because of the high radiation dose associated with it. Hence it has been easier for us to demonstrate in one study the ventilation and perfusion abnormalities faced by these patients.

Another important finding in our study was that therapeutic anticoagulation had no effect in improving the perfusion defects, as seen in all the patients (63.6%) who were on therapeutic anticoagulation. This is in keeping with the literature, where a multicentre autopsy study confirmed the presence of microthrombi in the pulmonary capillaries despite the fact that patients were on anticoagulation therapy.

Due to the retrospective nature of our study, a very important limitation is that our patient population did not have a baseline CT or VQ scan performed before COVID-19, hence we cannot completely
COVID-19 infection during the first wave of the pandemic in our facility. We strongly suspect that these findings are in keeping with a combination of pulmonary microthrombosis and small airway disease, and they are persistent for at least a year. There are likely more COVID-19 recovered patients all over the world who might not have been diagnosed with this complication. Although the long-term complications are not known, longstanding perfusion defects such as these could lead to pulmonary hypertension and right heart failure in the future, posing a serious public health issue. Future research is needed to determine the long-term persistence and effects of these matched perfusion defects after COVID-19 and its impact on patients, and methods to either prevent or treat it.

Declaration. None.

Acknowledgements. With their permission, the authors acknowledge all the radiographers, nurses and other staff in the Department of Nuclear Medicine at Universitas Academic Hospital.

Author contributions. OE was the major contributor in writing the article and interpreting the data. GE was a contributor in writing and proofreading the article. WE and TT played major roles in data collection. All authors read and approved the final manuscript and have given consent for publication of this article.

Funding. None.

Conflicts of interest. None.

Accepted 8 June 2022.